# Evaluation of TAM Receptor Targeting in Pathophysiology of Idiopathic Pulmonary Fibrosis

**Authors:** Nicole Vercellino, Luciana L. Ferreira, Elisa Zoppis, Alice Di Tizio, Zohre Sabihi Ahvaz, Rosalba Minisini, Francesco Gavelli, Pier Paolo Sainaghi, Filippo Patrucco, Mattia Bellan

PMC · DOI: 10.3390/medicina61101837 · Medicina · 2025-10-14

## TL;DR

This study investigates how blocking TAM receptors affects fibrosis in lung cells and macrophage interactions in idiopathic pulmonary fibrosis.

## Contribution

The study demonstrates that TAM receptor inhibition modulates fibroblast behavior and macrophage polarization in IPF.

## Key findings

- R428 significantly reduced pro-fibrotic gene expression in both IPF and control fibroblasts.
- R428 and LDC1267 inhibited fibroblast proliferation and migration more effectively in IPF cells.
- Co-culture experiments showed increased MRC1 expression, indicating macrophage polarization influenced by fibroblasts.

## Abstract

Background and Objectives: TAM receptors—Tyro3, Axl, and Mer—and their ligand Growth Arrest-Specific 6 (Gas6) represent a pleiotropic system implicated in fibrosis. Increased Gas6 and Axl expression have previously been observed in lung samples and fibroblast cultures from Idiopathic Pulmonary Fibrosis (IPF) patients. The study explored the contribution of Gas6/TAM system in fibrosis development and the impact of its pharmacological inhibition in fibroblasts. Materials and Methods: IPF fibroblasts (IPF FBs) and control human pulmonary fibroblasts (HPFs) were treated with R428 (Axl-specific inhibitor), LDC1267 (TAM inhibitor), or Nintedanib (an IPF-approved drug) to evaluate the influence of these drugs on cell proliferation, migration, and the expression of pro-inflammatory and pro-fibrotic genes. Fibroblast-to-myofibroblast differentiation was induced by TGF-β. The impact of IPF FBs and HPF on macrophage polarization was investigated through a co-culture of fibroblasts with monocyte-derived macrophages, with the further gene expression analysis of markers of the M1 (pro-inflammatory) or M2 (pro-fibrotic) polarization forms. Results: Cell proliferation was monitored in fibroblasts treated with TGF-β, the drugs, and their combination. In the presence of LDC1267 and Nintedanib, minor differences in cell confluence were detected between IPF FBs and HPFs; R428 (1 μM) seemed to have a higher inhibitory impact on IPF FBs. Regarding cell migration, the fibroblasts treated with LDC1267 exhibited slower wound closure. R428 treatment led to a relative wound closure of 76% in HPFs but only 56% in IPF FBs (60 h). R428 (1 μM) significantly reduced the expression of the pro-fibrotic markers ACTA2, COL1A1, and FN1 in HPFs and IPF FBs compared to TGF-β treatment. HPFs and IPF FBs co-cultured with monocyte-derived macrophages demonstrated a significantly increased expression of MRC1 while the expression of FN1, TNFα, and CXCL10 was moderately increased. Conclusions: These findings suggest that R428 and LDC1267 modulate the proliferation, migration, and gene expression of activated fibroblasts via TAM signaling. Fibroblast-mediated effects on macrophage polarization underscore the relevance of intercellular crosstalk in fibrotic disease.

## Linked entities

- **Genes:** TYRO3 (TYRO3 protein tyrosine kinase) [NCBI Gene 7301], AXL (AXL receptor tyrosine kinase) [NCBI Gene 558], GPER1 (G protein-coupled estrogen receptor 1) [NCBI Gene 2852], GAS6 (growth arrest specific 6) [NCBI Gene 2621], ACTA2 (actin alpha 2, smooth muscle) [NCBI Gene 59], COL1A1 (collagen type I alpha 1 chain) [NCBI Gene 1277], FN1 (fibronectin 1) [NCBI Gene 2335], MRC1 (mannose receptor C-type 1) [NCBI Gene 4360], TNF (tumor necrosis factor) [NCBI Gene 7124], CXCL10 (C-X-C motif chemokine ligand 10) [NCBI Gene 3627], TGFB1 (transforming growth factor beta 1) [NCBI Gene 7040]
- **Proteins:** GAS6 (growth arrest specific 6), R428 (hypothetical protein)
- **Diseases:** Idiopathic Pulmonary Fibrosis (MONDO:0800029), IPF (MONDO:0800504)
- **Species:** Homo sapiens (taxon 9606)

## Full-text entities

- **Genes:** TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, AXL (AXL receptor tyrosine kinase) [NCBI Gene 558] {aka ARK, AXL3, JTK11, Tyro7, UFO}, ACTA2 (actin alpha 2, smooth muscle) [NCBI Gene 59] {aka ACTSA, SMDYS}, TYRO3 (TYRO3 protein tyrosine kinase) [NCBI Gene 7301] {aka BYK, Dtk, Etk-2, RSE, Rek, Sky}, MRC1 (mannose receptor C-type 1) [NCBI Gene 4360] {aka CD206, CLEC13D, CLEC13DL, MMR, MRC1L1, bA541I19.1}, TGFB1 (transforming growth factor beta 1) [NCBI Gene 7040] {aka CAEND1, CED, DPD1, IBDIMDE, LAP, TGF-beta1}, GAS6 (growth arrest specific 6) [NCBI Gene 2621] {aka AXLLG, AXSF}, MERTK (MER proto-oncogene, tyrosine kinase) [NCBI Gene 10461] {aka MER, RP38, Tyro12, c-Eyk, c-mer}, COL1A1 (collagen type I alpha 1 chain) [NCBI Gene 1277] {aka CAFYD, EDSARTH1, EDSC, OI1, OI2, OI3}, FN1 (fibronectin 1) [NCBI Gene 2335] {aka CIG, ED-B, FINC, FN, FNZ, GFND}, CXCL10 (C-X-C motif chemokine ligand 10) [NCBI Gene 3627] {aka C7, IFI10, INP10, IP-10, SCYB10, crg-2}
- **Diseases:** inflammatory (MESH:D007249), fibrosis (MESH:D005355), IPF (MESH:D054990), fibrotic disease (MESH:D004194)
- **Chemicals:** TAM (MESH:D013629), R428 (MESH:C548378), LDC1267 (-), Nintedanib (MESH:C530716)
- **Species:** Homo sapiens (human, species) [taxon 9606]
- **Cell lines:** fibroblasts — Mus musculus (Mouse), Spontaneously immortalized cell line (CVCL_0594)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12566192/full.md

## Figures

11 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12566192/full.md

## References

69 references — full list in the complete paper: https://tomesphere.com/paper/PMC12566192/full.md

---
Source: https://tomesphere.com/paper/PMC12566192